Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation

<table>(a) Overall survival (OS), (b) disease-free survival (DFS), (c) overall survival curves according to the DRM evaluation, (d) disease-free survival curves according to the DRM evaluation.</table>

International Scholarly Research Notices

fig2

Figure 2

Figure 2: Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation 

Figure 2 | Detection of Minimal Residual Disease by Flow Cytometry for Patients with Multiple Myeloma Submitted to Autologous Hematopoietic Stem Cell Transplantation 